Triplet vs doublet adjuvant chemotherapy for gastric cancer: A systematic review and meta-analysis

Table 1 Characteristics of included studies

Ref.	Sample size (T/D)	Stage	Outcomes
Kang et al[4], 2021	353/466	II/III	ORR, DCR, OS, PFS, AEs
Al-Batran et al[6], 2019	143/205	I/II/III/IV	ORR, DCR, OS, AEs
Zhang et al[10], 2021	76/76	II/III	ORR, DCR, OS, PFS, AEs
Kang et al[19], 2024	749/321	II/III	ORR, DCR, OS, AEs
Al-Batran et al[20], 2016	451/73	I-IV	ORR, DCR, OS, PFS, AEs
Kurokawa et al[21], 2023	60/41	II/III	ORR, DCR, OS, AEs
Park et al[22], 2013	218/232	II/III	ORR, DCR, OS, PFS, AEs
Grizzi et al[23], 2022	107/107	II/III	ORR, DCR, OS, PFS, AEs
Tsuburaya et al[24], 2014	63/262	II/III	ORR, DCR, OS, PFS, AEs
Ni et al[25], 2021	20/45	II/III	ORR, DCR, OS, PFS, AEs
Yoshida et al[35], 2019	109/70	II/III	ORR, DCR, OS, PFS, AEs
Van Cutsem et al[36], 2006	117/92	I-IV	ORR, DCR, OS, PFS, AEs

T: Triplet chemotherapy regimen; D: Doublet chemotherapy regimen; ORR: Objective response rate; DCR: Disease control rate; OS: Overall survival; PFS: Progression-free survival; AEs: Adverse events.